Ontario Funds Prostate Cancer Treatment
This is a Ontario news story, published by torontosun, that relates primarily to Pluvicto news.
Ontario news
For more Ontario news, you can click here:
more Ontario newsPluvicto news
For more Pluvicto news, you can click here:
more Pluvicto newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newstorontosun news
For more news from torontosun, you can click here:
more news from torontosunAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
cancer treatment centres. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Toronto cancer hospital news, Pluvicto news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
advanced stage prostate cancertorontosun
•Ontario funding new treatment for advanced stage prostate cancer
69% Informative
Pluvicto is a targeted radioligand therapy, a radioactive drug that kills the specific cancer cells and uses a medical isotope that is produced in Ontario .
Health Canada approved the treatment in August 2022 , but patients have been waiting since then for coverage.
Ontario is the first jurisdiction to publicly fund and administer the treatment.
VR Score
66
Informative language
64
Neutral language
76
Article tone
semi-formal
Language
English
Language complexity
70
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links